3 results
Approved WMOCompleted
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).
Approved WMOCompleted
To assess the safety and efficacy of DBV712 in initiating desensitisation of peanut in children aged 1 to 3 years with peanut allergy, after 12 months of treatment with Epicutaneous Immunotherapy EPIT).
Approved WMORecruiting
The primary objective is to investigate whether pharmacological conditioning with S(+)-ketamine compared to pharmacological conditioning with placebo medication reduces pain sensitivity in patients with FMS.